This post highlights our team’s strong research performance and our experience at the FCEP Conference, Symposium by the Sea.
Read More
Dr. Jason Wilson revisits the use of fluvoxamine in the treatment of Covid-19. He discusses an exciting study recently published in Lancet Global Health that may change how doctors are treating Covid-19.
Read More
Dr. Jason Wilson discusses the ACTIV-4 trial. This trial is a part of Operation Warp Speed, a federal government funded effort to rapidly develop vaccines and therapeutic modalities to treat, prevent, or minimize side effects of Covid through the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) protocols. ACTIV-4 investigates the use of Abixiban and Aspirin in preventing VTE in Covid-19 patients.
Read More
Dr. Jason Wilson discusses a recent, small randomized controlled trial published in JAMA which investigated the use of fluvoxamine, an SSRI, as a therapeutic treatment option for Covid. The results of the study and the proposed mechanism are quite interesting. Find out why fluvoxamine is not ready for prime time, but SSRIs may deserve funding for larger clinical studies.
Read More
Residents and faculty have a unique opportunity to engage in research at USF. Let’s take a look back at where we’ve been, where we are, and where we are going under the direction of our Research Director, Dr. Jason Wilson.
Read More